Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals

Although sorafenib is currently used as a standard treatment for advanced hepatocellular carcinoma, low response rate, transient and limited efficacy, primary and acquired resistance and negative side-effects gain increasing attentions, suggesting the need for better efficacious combination therapy....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Death Dis
Main Authors: Xu, Junjie, Zheng, Longbo, Chen, Jiang, Sun, Yin, Lin, Hui, Jin, Ren-an, Tang, Minyue, Liang, Xiao, Cai, Xiujun
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5680567/
https://ncbi.nlm.nih.gov/pubmed/29022906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2017.411
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados